Andrea S. Blevins Primeau, PhD, MBA

Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.

All articles by Andrea S. Blevins Primeau, PhD, MBA

Gynecologic Cancer

Adjuvant Chemotherapy Does Not Improve PFS, OS in Locally Advanced Cervical Cancer

Andrea S. Blevins Primeau, PhD, MBA

April 25, 2023

Adding adjuvant chemotherapy to standard chemoradiotherapy does not improve outcomes in patients with locally advanced cervical cancer, a phase 3 study suggests.

General Oncology

Study Reveals High Markup of Cancer Drug Prices and Failure to Disclose Prices Publicly

Andrea S. Blevins Primeau, PhD, MBA

April 27, 2022

The median price markup was as high as 633.6% for 1 drug.

General Oncology

Inflammatory Markers May Predict Long COVID in Patients With Solid Tumors

Andrea S. Blevins Primeau, PhD, MBA

April 26, 2022

An elevated C-reactive protein level and an elevated neutrophil-to-lymphocyte ratio were both associated with an increased risk of long COVID.

Brain Cancer

Temozolomide Bests Nivolumab in Glioblastoma With Unmethylated MGMT Promoter

Andrea S. Blevins Primeau, PhD, MBA

April 19, 2022

Overall and progression-free survival were superior with temozolomide.

General Oncology

Half of Cancer Patients Lost Neutralizing Antibodies 6 Months After COVID-19 Vaccination

Andrea S. Blevins Primeau, PhD, MBA

March 25, 2022

Roughly half of patients with hematologic cancers or solid tumors lost neutralizing antibody responses to SARS-CoV-2 variants of concern at 6 months after vaccination.